- Home
- DUO vs INDP Comparison
DUO vs INDP Comparison
Compare DUO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- INDP
- Stock Information
- Founded
- DUO 2011
- INDP 2000
- Country
- DUO China
- INDP United States
- Employees
- DUO N/A
- INDP N/A
- Industry
- DUO Real Estate
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- DUO Finance
- INDP Health Care
- Exchange
- DUO Nasdaq
- INDP Nasdaq
- Market Cap
- DUO 6.1M
- INDP 6.0M
- IPO Year
- DUO 2019
- INDP N/A
- Fundamental
- Price
- DUO $3.90
- INDP $4.38
- Analyst Decision
- DUO
- INDP Strong Buy
- Analyst Count
- DUO 0
- INDP 2
- Target Price
- DUO N/A
- INDP $238.00
- AVG Volume (30 Days)
- DUO 1.1M
- INDP 1.5M
- Earning Date
- DUO 11-19-2025
- INDP 11-11-2025
- Dividend Yield
- DUO N/A
- INDP N/A
- EPS Growth
- DUO N/A
- INDP N/A
- EPS
- DUO N/A
- INDP N/A
- Revenue
- DUO $56,189,313.00
- INDP N/A
- Revenue This Year
- DUO N/A
- INDP N/A
- Revenue Next Year
- DUO N/A
- INDP N/A
- P/E Ratio
- DUO N/A
- INDP N/A
- Revenue Growth
- DUO 48.30
- INDP N/A
- 52 Week Low
- DUO $1.24
- INDP $2.22
- 52 Week High
- DUO $33.92
- INDP $58.24
- Technical
- Relative Strength Index (RSI)
- DUO 55.00
- INDP 48.71
- Support Level
- DUO $3.03
- INDP $2.86
- Resistance Level
- DUO $3.78
- INDP $5.14
- Average True Range (ATR)
- DUO 0.37
- INDP 1.00
- MACD
- DUO -0.07
- INDP 0.27
- Stochastic Oscillator
- DUO 39.62
- INDP 19.63
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.